AlphAIAlphAI — Financial news for AI agents
marketscreener.com

UBS Initiates Coverage on AptarGroup With Neutral Rating, $135 Price Target

UBS initiated coverage on AptarGroup with a neutral rating and a $135 price target. The company's stock is currently trading at $121.81. Recent events include management changes and a presentation at the Wells Fargo Healthcare Conference.

Original reporting
marketscreener.com
Published Oct 9, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 12:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$ATR
Relevance
6/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

Med
01

Why it matters

The new coverage provides fresh analyst insight, which can influence short‑term trading decisions.

02

Market read

Analyst initiation is a primary catalyst for the stock, offering a modest trading opportunity.

03

What to watch

Potential supply‑chain constraints or upcoming contract wins that are not yet disclosed could affect the stock.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

UBS released its first research report on AptarGroup, assigning a neutral rating and a $135 price target.

Market effects

Sector

Coverage may slightly lift the packaging and dispensing sector as peers are re‑rated.

Regional

Primarily U.S. market impact; limited regional effect.

Global

Low global relevance beyond AptarGroup investors.

Counterpoint

What could challenge this read

Some investors may view the neutral rating as a signal to stay on the sidelines until clearer growth catalysts emerge.

Key entities

  • company
    AptarGroup Inc.

    Manufacturer of dispensing and packaging solutions, ticker APT.

  • financial_institution
    UBS

    Global investment bank that initiated coverage on AptarGroup.

Read at source← All news

Related articles

$ATRHighAI 8/10

Aptar Q3 2026 slides: broad growth, strong Pharma pipeline

AptarGroup (NYSE:ATR) reported Q3 2026 sales of $1.019B, up 6% YoY, with adjusted EPS of $1.52 beating estimates. Growth was seen across all segments, but margins were pressured. The Pharma segment grew 2% reported, 1% core, while Beauty grew 9% reported, 8% core, and Closures grew 11%. Management expects Q4 adjusted EPS of $1.39-$1.47, up 17% YoY.

investing.com
$ATRMed

AptarGroup Inc (ATR) (Q3 2026) Earnings Call Highlights: Core Sales Grow 5% as Pharma

AptarGroup Inc (ATR) reported Q3 2026 core sales growth of 5% across all segments, with Pharma, Beauty, and Closures up 8%, 8%, and 11% respectively. Adjusted EPS was $1.52, down 6% YoY. Pharma growth was impacted by emergency medicine destocking, expected to affect full-year sales by $65M. Beauty and Closures margins declined due to operational challenges. CEO Gael Touya outlined plans for multi-year transformation in Beauty and reiterated long-term growth targets for Pharma.

finance.yahoo.com
$ATRMedAI 8/10

What AptarGroup (ATR) Said on Its Q3 Earnings Call

AptarGroup (ATR) reported Q3 earnings, highlighting growth in beauty, closures, and pharma sectors. Beauty core sales rose 8%, while closures saw 11% growth. Pharma developments include collaborations and acquisitions. The company recorded a $61.2M charge related to its Russian subsidiary. ATR forecasted Q4 adjusted EPS of $1.39-$1.47, up 17% YoY. Full-year capex is expected at $260M-$280M. Virginie Maes will lead Aptar Pharma starting January 1.

finance.yahoo.com